Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 1, 1997, Pages 107-113

  Goldbourt, Uri ^a,d   Yaari, Shlomit ^b   Medalie, Jack H ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

coronary heart disease; HDL cholesterol; long term mortality; preventive strategies

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE;

EID: 0031029838     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.1.107     Document Type: Article

References (32)

1. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and development of ischemic heart disease. Lancet. 1975;1:16-20.
2. Yaari S, Goldbourt U, Even-Zohar S, Neufeld HN. Serum HDL and total cholesterol: associations with total, cardiovascular and cancer mortality in a seven-year prospective study of 10,000 men. Lancet, 1981;1:1011-1015.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
4. Bucher KD, Friedlander Y, Kaplan EB, et al. Biological and cultural sources of familial resemblance in plasma lipids: a comparison between North America and Israel: the Lipid Research Clinics Program. Genet Epidemiol. 1988;5:17-33.
5. Rader DJ, Brewer HB Jr. Lipids, apolipoproteins and lipoproteins. In: Goldbourt U, de Faire U, Berg K, eds. Genetic Factors in Coronary Heart Disease. Dordrecht, Netherlands: Kluwer; 1994:83-103.
6. Sagiv M, Goldbourt U. The influence of physical exercise on blood levels of HDL-cholesterol: implications for the risk of coronary heart disease. Int J Sports Med. 1994;15:261-266.
7. Taskinen MR, Nikkila EA, Valimaki M, Sane T, Kuusi T, Kesaniemi A, Ylikahri R. Alcohol-induced changes in serum lipoproteins and in their metabolism. Am Heart J. 1987;113:458-464.
8. Goldbourt U, Medalie JH. Characteristics of smokers, non-smokers and ex-smokers among 10,000 adult males in Israel, II: physiological, biochemical and genetic characteristics. Am J Epidemiol. 1977;105:75-86.
9. Wood PD, Stefanick MI, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM, Elsworth NM, Terry RB, Haskell WL. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med. 1988;319:1173-1179.
10. Strisower EH, Adamson G, Strisower B. Treatment of hyperlipidemizs. Am J Med. 1968;45:488-501.
11. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, et al. Rationale and design of a secondary prevention trial of elevating serum high-density lipoprotein cholesterol and reducing triglyceride in patients with clinically manifest atherosclerotic heart disease: the Bezafibrate Infarction Prevention Trial. Am J Cardiol. 1993;71:909-915.
12. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for the secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA. 1993;269:3015-3023.
14. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA. 1984;251:351-374.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383-1389.
16. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees: a 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 1993;82:100-121.
17. Groen JJ, Medalie JH, Neufeld HN, Riss E, Bachrach CA, Mount FW, Smith HA. An epidemiologic investigation of hypertension and ischemic heart disease within a defined segment of the adult male population of Israel. Isr J Med Sci. 1968;4:177-194.
18. Anderson JT, Keys A. Cholesterol in serum lipoprotein fractions. Clin Chem. 1962;21:145-159.
19. Burstein M, Samaille J. Sur une dosage rapide du cholesterol lie aux alpha- et aux beta-lipoproteines du serum. Clin Chim Acta. 1960;5:609-611.
20. Yaari S, Goldbourt U. A SAS program for evaluating person years of risk in cohort studies. Comput Biol Med. 1989;19:353-359.
21. Gahlinger PM, Abramson JH. RATES2: comparison of persontime incidence rates. Version 1.4. Computer Programs for Epidemiologic Analysis. Honolulu, Hawaii: Makapuu Medical Press; 1993:119-125.
22. Cox DR. Regression models and life tables. J R Stat Soc (Ser B). 1972;34:187-202.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. The LIFETEST Procedure. In: SAS/STAT User's Guide, Vol 2, GLMVARCOMP. Version 6, 4th ed. Cary, NC: SAS Institute; 1990:1028-1069.
25. Goldbourt U, Yaari S. Cholesterol and CHD mortality: a 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990;10:512-519.
26. Luepker RV, Sprafka JM, McGovem PC, Hannan PJ, Blackburn H. Isolated low HDL cholesterol as a risk factor for coronary heart disease. Circulation. 1993;88(suppl I, part 2):I-511. Abstract.
27. Sacks FM. Desirable serum total cholesterol with low HDL cholesterol levels: an undesirable situation in coronary heart disease. Circulation. 1992;86:1341-1344.
28. Goldschmid MG, Barret-Connor E, Edelstein SL, Wingard DL, Cohn BA, Herman WH. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation. 1994;89:991-997.
29. Fontbonne A, Eschwege E, Cambien F, Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen J. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes:- results from 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32:300-304.
30. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primarypreventive trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
31. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of total cholesterol. Circulation. 1992;86:1165-1170.
32. Goldbourt U, Benderly M, Graff E, Mandelzweig L, for the BIP Study Group. Lipids and lipoproteins in symptomatic coronary heart disease: distribution, intercorrelation, and significance for risk classification in 6,700 men and 1,500 women. Circulation. 1992;86:839-848.